Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice

Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice

Endothelial dysfunction contributes to the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD). Pemafibrate has been shown to ameliorate MASLD in basic and clinical studies, but it is unclear whether it is also effective in the status of endothelial dysfunction. An MASLD...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsuneyama, Yasumasa Ikeda, Ken-ichi Aihara
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Antioxidants
Subjects:
MASLD
pemafibrate
eNOS
endothelial dysfunction
oxidative stress
NADPH oxidase
Online Access:https://www.mdpi.com/2076-3921/14/7/891
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.mdpi.com/2076-3921/14/7/891

Similar Items